Is Bioparma a Gate Keeper of the Diagnostics Industry?

i'll take the side that we should continue, you know, to leverage our traditional payer systems and regulatory framework for diagnostics. Lots of interesting companies are doing this now, for check point inhibitors, in the ocology space, companies are even a t point about second order diagnostics developing entirely. Am treating most diseases earlier reduces long term cost of care. Not always, but often does identifying patients who won't a benefit, for example, from atherapy. And i think payers have a huge amount to gain by using digital diagnastics.